Abstract
Background and Aims: The symptoms of postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), the two subtypes of functional dyspepsia (FD) under the new Rome III classification, tend to overlap with those of non-erosive reflux disease (NERD). Plasma ghrelin levels have been associated with gastric motility; however, clinical studies have yet to examine this relationship among patients with PDS, EPS or NERD. Thus, this study aims to evaluate the correlation between gastric emptying and ghrelin levels as possible candidate factors for gastric motility in these diseases. Methods: One hundred and fifty-one patients presenting with typical symptoms of FD (EPS, n = 36; PDS, n = 76) or NERD (n = 39), and 20 healthy volunteers were enrolled. Gastric motility was evaluated with the Tmax value as a marker of gastric emptying using the 13C-acetate breath test. We used Rome III criteria to evaluate upper abdominal symptoms, and SRQ-D scores to determine depression status. We measured both acylated and des-acylated ghrelin levels by ELISA methods. Results: The Tmax value in PDS patients was significantly higher than in healthy volunteers. Acylated ghrelin levels were significantly lower in NERD and PDS patients than in healthy volunteers. Interestingly, there was significant correlation between the acylated ghrelin levels and Tmax value in PDS patients but not in EPS or NERD patients. Conclusion: Our results suggest that acylated ghrelin might play an important role in the pathophysiology of PDS patients through its effect on gastric emptying.
Journal Section:
Original Paper
References
1.
Fischer H, Heidemann T, Hengst K, Domschke W, Konturek JW: Disturbed gastric motility and pancreatic hormone release in diabetes mellitus. J Physiol Pharmacol 1998;49:529–541.
[PubMed]
2.
Quigley EM: Gastric emptying in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004;20(suppl 7):56–60.
[PubMed]
3.
Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V: Functional gastroduodenal disorders. Gastroenterology 2006;130:1466–1479.
[PubMed]
4.
Talley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN: Functional gastroduodenal disorders. Gut 1999;45(suppl 2):II37–II42.
5.
Quigley EMM: Gastric motor and sensory function, and motor disorders of the stomach; in Feldman M, Friedman LS, Sleisenger MH (eds): Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management. Philadelphia, Saunders, 2002, pp 691–714.
6.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
[PubMed]
7.
Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000;276:905–908.
[PubMed]
8.
Asakawa A, Inui A, Fujimiya M, Sakamaki R, Shinfuku N, Ueta Y, Meguid MM, Kasuga M: Stomach regulates energy balance via acylated ghrelin and desacyl ghrelin. Gut 2005;54:18–24.
[PubMed]
9.
Chen CY, Chao Y, Chang FY, Chien EJ, Lee SD, Doong ML: Intracisternal des-acyl ghrelin inhibits food intake and non-nutrient gastric emptying in conscious rats. Int J Mol Med 2005;16:695–699.
[PubMed]
10.
Drossman DA: The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377–1390.
[PubMed]
11.
Dickman R, Bautista JM, Wong WM, Bhatt R, Beeler JN, Malagon I, Risner-Adler S, Lam KF, Fass R: Comparison of esophageal acid exposure distribution along the esophagus among the different gastroesophageal reflux disease groups. Am J Gastroenterol 2006;101:2463–2469.
[PubMed]
12.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.
[PubMed]
13.
Hellmig S, Von Schoning F, Gadow C, Katsoulis S, Hedderich J, Folsch UR, Stuber E: Gastric emptying time of fluids and solids in healthy subjects determined by 13C breath tests: influence of age, sex and body mass index. J Gastroenterol Hepatol 2006;21:1832–1838.
[PubMed]
14.
Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd: Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259–1268.
[PubMed]
15.
Castillo EJ, Camilleri M, Locke GR, Burton DD, Stephens DA, Geno DM, Zinsmeister AR: A community-based, controlled study of the epidemiology and pathophysiology of dyspepsia. Clin Gastroenterol Hepatol 2004;2:985–996.
[PubMed]
16.
Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998;115:1346–1352.
[PubMed]
17.
Lunding JA, Tefera S, Gilja OH, Hausken T, Bayati A, Rydholm H, Mattsson H, Berstad A: Rapid initial gastric emptying and hypersensitivity to gastric filling in functional dyspepsia: effects of duodenal lipids. Scand J Gastroenterol 2006;41:1028–1036.
[PubMed]
18.
Moayyedi P, Deeks J, Talley NJ, Delaney B, Forman D: An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews. Am J Gastroenterol 2003;98:2621–2626.
[PubMed]
19.
Armstrong D: Helicobacter pylori infection and dyspepsia. Scand J Gastroenterol 1996;215:38–47.
20.
Strauss RM, Wang TC, Kelsey PB, Compton CC, Ferraro MJ, Perez-Perez G, Parsonnet J, Blaser MJ: Association of Helicobacter pylori infection with dyspeptic symptoms in patients undergoing gastroduodenoscopy. Am J Med 1990;89:464–469.
[PubMed]
21.
Talley NJ, Janssens J, Lauritsen K, Racz I, Bolling-Sternevald E: Eradication of Helicobacter pylori in functional dyspepsia: randomized double blind placebo controlled trial with 12 months’ follow up. BMJ 1999;318:833–837.
[PubMed]
22.
McColl K, Murray L, El-Omar E, Dickson A, El-Nujumi A, Wirz A, Kelman A, Penny C, Knill-Jones R, Hilditch T: Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. N Engl J Med 1998;339:1869–1874.
[PubMed]
23.
Quartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW: Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998;43:2028–2033.
[PubMed]
24.
Tack J, Bisschops R, Sarnelli G: Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004;127:1239–1255.
[PubMed]
25.
Sarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J: Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003;98:783–788.
[PubMed]
26.
Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP: Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995;37:457–464.
[PubMed]
27.
Fass R, Naliboff B, Higa L, Johnson C, Kodner A, Munakata J, Ngo J, Mayer EA: Differential effect of long-term esophageal acid exposure on mechanosensitivity and chemosensitivity in humans. Gastroenterology 1998;115:1363–1373.
[PubMed]
28.
Kamolz T, Velanovich V: Psychological and emotional aspects of gastroesophageal reflux disease. Dis Esophagus 2002;15:199–203.
[PubMed]
29.
Jones MP, Roth LM, Crowell MD: Symptom reporting by functional dyspeptics during the water load test. Am J Gastroenterol 2005;100:1334–1339.
[PubMed]
30.
Kovacs Z, Kerekgyarto O: Psychological factors, quality of life, and gastrointestinal symptoms in patients with erosive and non-erosive reflux disorder. Int J Psychiatry Med 2007;37:139–150.
[PubMed]
31.
Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML: Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997;32:965–973.
[PubMed]
32.
Fass R, Ofman JJ: Gastroesophageal reflux disease – should we adopt a new conceptual framework? Am J Gastroenterol 2002;97:1901–1909.
[PubMed]
33.
Martinez SD, Malagon IB, Garewal HS, Cui H, Fass R: Non-erosive reflux disease (NERD) – acid reflux and symptom patterns. Aliment Pharmacol Ther 2003;17: 537–545.
[PubMed]
34.
Carmagnola S, Fraquelli M, Cantu P, Conte D, Penagini R: Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease. Scand J Gastroenterol 2006;41:767–772.
[PubMed]
35.
Scheffer RC, Tatum RP, Shi G, Akkermans LM, Joehl RJ, Kahrilas PJ: Reduced tLESR elicitation in response to gastric distension in fundoplication patients. Am J Physiol Gastrointest Liver Physiol 2003;284:G815–G820.
[PubMed]
36.
Penagini R, Carmagnola S, Cantu P, Allocca M, Bianchi PA: Mechanoreceptors of the proximal stomach: role in triggering transient lower esophageal sphincter relaxation. Gastroenterology 2004;126:49–56.
[PubMed]
37.
Zerbib F, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP: H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G350–G356.
[PubMed]
38.
Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P: Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002;282:G948–G952.
[PubMed]
39.
Herculano JR Jr, Troncon LE, Aprile LR, Morases ER, Secaf M, Onofre PH, Dantas RO, Oliveira RB: Diminished retention of food in the proximal stomach correlates with increased acidic reflux in patients with gastroesophageal reflux disease and dyspeptic symptoms. Dig Dis Sci 2004;49:750–756.
[PubMed]
40.
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA, Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 2001;86:5992.
[PubMed]
41.
Tack J, Depoortere I, Biosschops R, Verbeke K, Janssens J, Peeters T: Influence of ghrelin on gastric emptying and meal-related symptoms in idiopathic gastroparesis. Aliment Pharmacol Ther 2005;22:847–853.
[PubMed]
42.
Tack J, Deoportere I, Bisschops R, Delporte C, Coulie B, Meulemans A, Janssens J, Peeters T: Influence of ghrelin on interdigestive gastrointestinal motility in humans. Gut 2006;55:327–333.
[PubMed]
43.
Shinomiya T, Fukunaga M, Akamizu T, Irako T, Yokode M, Kangawa K, Nakai Y, Nakai Y: Plasma acylated ghrelin levels correlate with subjective symptoms of functional dyspepsia in female patients. Scand J Gastroenterol 2005;40:648–653.
[PubMed]
44.
Takamori K, Mizuta Y, Takeshima F, Akazawa Y, Isomoto H, Ohnita K, Ohba K, Omagari K, Shikuwa S, Kohno S: Relation among plasma ghrelin level, gastric emptying, and psychologic condition in patients with functional dyspepsia. J Clin Gastroenterol 2007;41:477–483.
[PubMed]
45.
Lanzini A, Magni P, Petroni ML, Motta M, Lanzarotto F, Villanacci V, Amato M, Mora A, Bertolazzi S, Benini F, Ricci C: Circulating ghrelin level is increased in coeliac disease as in functional dyspepsia and reverts to normal during gluten-free diet. Aliment Pharmacol Ther 2006;23:907–913.
[PubMed]
46.
Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M, Kangawa K: Ghrelin stimulates gastric acid secretion and motility in rats. Biochem Biophys Res Commun 2000;276:905–908.
[PubMed]
47.
Kitazawa T, De Smet B, Verbeke K, Depoortere I, Peeters TL: Gastric motor effects of peptide and non-peptide ghrelin agonists in mice in vivo and in vitro. Gut 2005;54:1078–1084.
[PubMed]
48.
Trudel L, Tomasetto C, Rio MC, Bouin M, Plourde V, Eberling P, Poitras P: Ghrelin/motilin-related peptide is a potent prokinetic to reverse gastric postoperative ileus in rat. Am J Physiol Gastrointest Liver Physiol 2002;282:G948–G952.
[PubMed]
49.
Osawa H, Nakazato M, Date Y, Kita H, Ohnishi H, Ueno H, Shiiya T, Satoh K, Ishino Y, Sugana K: Impaired production of gastric ghrelin in chronic gastritis associated with Helicobacter pylori. J Clin Endocrinol Metab 2005;90:10–16.
[PubMed]
50.
Suzuki H, Masaoka T, Hosoda H, Nomura S, Ohara T, Kangawa K, Ishii H, Hibi T: Plasma ghrelin concentration correlates with the levels of serum pepsinogen I and pepsinogen I/II ratio – a possible novel and non-invasive marker for gastric atrophy. Hepatogastroenterology 2004;51:1249–1254.
[PubMed]
51.
Rashed H, Cutts T, Abell T, Cowings P, Toscano W, El-Gammal A, Adl D: Predictors of response to a behavioral treatment in patients with chronic gastric motility disorders. Dig Dis Sci 2002;47:1020–1026.
[PubMed]
© 2009 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2009
You do not currently have access to this content.
